Trial Profile
An Open, Non-controlled, Parallel, Ascending Multiple-dose, Multicenter Study to Assess Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of SOBI003 in Pediatric MPS IIIA Patients
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 09 Feb 2023
Price :
$35
*
At a glance
- Drugs SOBI 003 (Primary)
- Indications Mucopolysaccharidosis III
- Focus Adverse reactions; First in man
- Sponsors Swedish Orphan Biovitrum
- 01 Apr 2020 Status changed from active, no longer recruiting to completed.
- 21 Mar 2020 This trial has been discontinued in Germany, as per European Clinical Trials Database record
- 18 Feb 2020 Planned End Date changed from 1 Jan 2020 to 1 Feb 2020.